论文部分内容阅读
因血栓形成引起的心脑血管病和外周血管病是严重危害人类生命的常见病。因此,溶栓治疗是重要的医学课题。已有的溶纤剂如尿激酶、链激酶以及国外新近用基因工程方法生产的r—TPA(组织型纤维蛋白溶酶原激活剂)等在实际应用中各有弊端。
Cardio-cerebrovascular diseases and peripheral vascular diseases caused by thrombosis are common diseases that seriously harm human life. Therefore, thrombolytic therapy is an important medical issue. Existing fibrinolytic agents such as urokinase, streptokinase, and r-TPA (tissue plasminogen activator) recently produced by genetic engineering methods in foreign countries have their drawbacks in practical applications.